Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area (Neurological Disorders, Cardiovascular Disease), By Technology (PCR, In-situ Hybridization), By Region, And Segment Forecasts, 2025 - 2030

Pharmacogenomics Technology Market Growth & Trends

The global pharmacogenomics technology market is anticipated to reach USD 12.38 billion by 2030 and is anticipated to expand at a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient’s therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights

• Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
• Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
• Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
• North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
• Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
• Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
• In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.